Exacerbation of Whipple's disease associated with infliximab treatment

Scandinavian Journal of Rheumatology

Volumn 34, Issue 2, 2005, Pages 148-151

  Kneitz, C ^a   Suerbaum, S ^b   Beer, M ^a   Muller J ^b   Jahns, R ^a   Tony, H P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BACTERIAL DNA; C REACTIVE PROTEIN; CORTICOSTEROID; COTRIMOXAZOLE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; CHRONIC ARTHRITIS; DIARRHEA; DISEASE EXACERBATION; ELECTRON MICROSCOPY; ERYTHEMA NODOSUM; FEVER; FISTULA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE LIPODYSTROPHY; JUVENILE RHEUMATOID ARTHRITIS; LAPAROTOMY; LYMPHADENOPATHY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TROPHERYMA WHIPPELII; WASTING SYNDROME; WEIGHT REDUCTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DNA, BACTERIAL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIA; HUMANS; ILEUM; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER; LYMPH NODES; MALE; METHOTREXATE; POLYMERASE CHAIN REACTION; STILL'S DISEASE, ADULT-ONSET; SULFAMETHIZOLE; TREATMENT OUTCOME; TRIMETHOPRIM; WHIPPLE DISEASE;

EID: 18844409586     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740510015230     Document Type: Article

References (10)

1. Puéchal X. Whipple disease and arthritis. Curr Opin Rheumatol 2001;13:74-9.
2. Fleming JL, Wiesner RH. Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc 1988;63:539-51.
3. Durand DV, Lecomte C, Cathebras P, Rousset H, Godeau P. Whipple's disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple's Disease. Medicine 1997;76:170-84.
4. Black-Schaffer B. The tinctorial demonstration of a glycoprotein in Whipple's disease. Proc Soc Exp Biol Med 1949;72:225-7.
5. von Herbay A, Ditton HJ, Schuhmacher F, Maiwald M. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebral fluid. Gastroenterology 1997;113:434-41.
6. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New Engl J Med 2001;345:1098-104.
7. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-63.
8. Bjerkness R, Odegaard S, Bjerkvig R, Borkje B, Laerum OD. Whipple's disease: demonstration of a persisting monocyte and macrophage dysfunction. Scand J Gastroenterol 1988;23:611-19.
9. Gardam MA, Keystone EC, Menzies RM, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
10. Marth T, Kleen N, Stallmach A, Ring S, Aziz S, Schmidt C, et al. Dysregulated peripheral and mucosal Th1/Th2 response in Whipple's disease. Gastroenterology 2002;123:1468-77.